NCT03617588View on ClinicalTrials.gov

68Ga-THP-PSMA PET/CT Imaging in High Risk Primary Prostate Cancer or Biochemical Recurrence of Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

June 18, 2018

Primary Completion Date

June 12, 2019

Study Completion Date

June 12, 2019

Conditions
Prostate Cancer
Interventions
DRUG

Gallium-68 THP-PSMA

Subjects will undergo a Gallium-68 THP-PSMA scan in addition to standard of care monitoring. The results of this scan may influence the patient management plan.

Trial Locations (4)

EC1A 7BE

St Bartholomew's Hospital (PIC), London

NW3 2QG

Royal Free Hospital (PIC), London

Unknown

Guy's and St Thomas' Hospital (PIC), London

University College Hospital London, London

All Listed Sponsors
lead

Theragnostics Ltd

INDUSTRY

NCT03617588 - 68Ga-THP-PSMA PET/CT Imaging in High Risk Primary Prostate Cancer or Biochemical Recurrence of Prostate Cancer | Biotech Hunter | Biotech Hunter